Who owns Edgewise Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of EWTX from SEC Form 13F filings across 225 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 225 institutions disclosed 119.2M shares of Edgewise Therapeutics, Inc. worth $4.82B — about 110.7% of shares outstanding; the largest disclosed holder is ORBIMED ADVISORS LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
225
13F holders
$4.82B
value, 2026 filers
110.7%
of shares outstanding (119.2M sh)
41
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of EWTX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 15.5M | $630.5M | 11.7% | 14.4% | 0.0% |
| 2 | Paradigm Biocapital Advisors LP | 10.2M | $415.1M | 7.8% | 9.5% | +38.7% |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 8.4M | $341.0M | 3.0% | 7.8% | -19.5% |
| 4 | BlackRock, Inc. | 6.6M | $268.4M | 0.0% | 6.1% | +2.1% |
| 5 | Jupiter Topco LLCNEW | 6.1M | $246.9M | 0.1% | 5.6% | new |
| 6 | FMR LLC | 5.5M | $223.0M | 0.0% | 5.1% | +439.7% |
| 7 | NOVO HOLDINGS A/S | 5.3M | $217.4M | 12.6% | 5% | 0.0% |
| 8 | Driehaus Capital Management LLC | 4.7M | $192.1M | 1.1% | 4.4% | +5.6% |
| 9 | PERCEPTIVE ADVISORS LLC | 4.4M | $177.7M | 2.7% | 4.1% | -1.1% |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 3.9M | $156.9M | 0.0% | 3.6% | +1.9% |
| 11 | BAKER BROS. ADVISORS LP | 3.7M | $150.4M | 0.8% | 3.4% | -43.7% |
| 12 | Siren, L.L.C. | 3.2M | $129.4M | 2.6% | 3% | -28.1% |
| 13 | Cormorant Asset Management, LP | 2.5M | $102.0M | 5.2% | 2.3% | -23.0% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 2.2M | $88.3M | 0.0% | 2% | +21.5% |
| 15 | ALLIANCEBERNSTEIN L.P. | 2.1M | $66.7M | 0.0% | 2% | +23.0% |
| 16 | Integral Health Asset Management, LLC | 2.0M | $81.3M | 3.2% | 1.9% | +25.0% |
| 17 | BRAIDWELL LP | 2.0M | $81.1M | 3.0% | 1.9% | -14.9% |
| 18 | MORGAN STANLEY | 1.9M | $79.2M | 0.0% | 1.8% | -13.2% |
| 19 | STATE STREET CORP | 1.8M | $74.3M | 0.0% | 1.7% | +6.5% |
| 20 | MPM BIOIMPACT LLC | 1.6M | $65.9M | 4.0% | 1.5% | -2.4% |
| 21 | BANK OF AMERICA CORP /DE/ | 1.6M | $63.3M | 0.0% | 1.4% | +17.4% |
| 22 | Qube Research & Technologies Ltd | 1.3M | $50.9M | 0.0% | 1.2% | +51.7% |
| 23 | DIMENSIONAL FUND ADVISORS LP | 1.1M | $46.3M | 0.0% | 1.1% | -6.6% |
| 24 | AMERICAN CENTURY COMPANIES INC | 1.1M | $45.8M | 0.0% | 1% | -1.8% |
| 25 | First Light Asset Management, LLC | 1.1M | $44.5M | 2.7% | 1% | +9.3% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.